Translational Cancer Research Prize

This prize recognises the cutting edge breakthroughs of an outstanding research team that has united in the quest to ensure scientific discoveries benefit patients and the public.

Key information

Awarded to

Awarded to

Teams who have made tangible impact through translational research

Prize value

Prize value


Key dates

Nominations open

November 2017


Nominations close

31 March 2018

The winning team will also receive free attendance at the NCRI Annual Conference for up to five members of the team, where the presentation ceremony will take place. The representative institutions will be cited at the conference for their leadership role in fostering the team and supporting their science.

Make a nomination

The Translational Cancer Research Prize is awarded annually to an outstanding multidisciplinary cancer research team nominated by their peers and selected by an international panel.

Nominations may be made on behalf of or by the translational research team. Any senior member of a team may serve as the corresponding nominator.

  • For the purpose of this Prize, a team is comprised of researchers providing complementary interdisciplinary expertise, each of whom has made separate substantive and quantifiable contributions to the research being recognised.
  • Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government.
  • Team members may be working within the same institution or at several institutions; not restricted to those in the UK only. However, a significant proportion of the work that is being honoured must have been carried out in the UK.
  • If researchers are in the same institution, they must have clearly separate funding and research space or in the case of a large research group be part of different teams.
  • The research to be recognised should reflect work towards a specific scientific goal that otherwise would not be realized by any single component of the team.
  • Teams comprising academic and industry researchers will be accepted.
  • Nominations must be within the remit of a translational research project - see additional notes.

The prize-winning team is expected to be multidisciplinary, and comprise both clinical and non-clinical members - the team may also include principal investigators and non-principal investigators. Team members do not necessarily have to come from the same country or belong to the same institution; a significant proportion of the work that is being honoured must have been carried out in the UK.

Additional notes

As defined by the National Cancer Institute: "Translational cancer research transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications to reduce cancer incidence, morbidity, and mortality."

Translational cancer research provides a 'bench to bedside' approach for patient care. It covers all aspects of drug discovery and biomarker research, and involves basic scientists providing clinicians with new tools for use in patients and for assessment of their impact. It also covers clinical researchers making novel observations about the nature and progression of disease that often stimulate basic investigations and drug discovery.

The Translational Cancer Research Prize recognises and acknowledges the impact of translational research in the continuing effort to prevent, diagnose and cure cancer.

Nominations that focus on excellent basic research, but which have not exploited translational opportunities as part of the nominated research, are not within the remit of this Prize.

If you are unclear whether a proposed nomination is within remit, please contact the Office.

To nominate, the following materials must be submitted:

  1. A completed nomination form including:
    • A description in no more than 2500 words of the accomplishment(s) for which the team is being nominated, and in no more than 1000 words, a description of the value-added activities of the team and the coordination of the research across the multiple research sites. Please also state the Prize for which they are nominated.
    • A descriptive list of institutional support of the team.
    • Electronic signatures of all team members.
  2. Abbreviated CVs for all team members including a list of their 10 most relevant publications.
  3. Letters of endorsement from the Dean, Department Head or Director of all institutions represented by the team members, confirming support for the nomination and certifying contents of the nomination package.

Download a nominations form

Nominations may be made by any scientist, who is now or has been, affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science (corresponding nominator). Any senior member of a team may serve as the corresponding nominator.

Nominators are asked to maintain the confidentiality of the nomination process.

Nominations must be submitted electronically to Paper nominations will not be accepted. A nomination should not be considered submitted until Cancer Research UK has issued an email confirming this. Confirmations will be sent within five working days.

Please note that the deadline is final and we cannot accept nominations after 5 p.m. on the day of the deadline.

Dr Susana Sequeira
Research Funding Manager
Tel: +44 (0) 20 3469 5331

Prizewinners of 2016

CRUK Research Prizes Ceremony at NCRI Conference 2016 (Simon Callaghan Photography)

We've awarded our annual Research Prizes to five exceptional researchers at our annual prize giving ceremony at the NCRI Conference, including a Lifetime Achievement Prize to Professor Stan Kaye for his achievements in drug development.

Share this page